10-Q 1 rgbp033122form10q.htm 10-Q
0001589150 false 09/30 2022 Q2 0001589150 2021-10-01 2022-03-31 0001589150 2022-04-07 0001589150 2022-03-31 0001589150 2021-09-30 0001589150 us-gaap:SeriesAPreferredStockMember 2022-03-31 0001589150 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2022-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-09-30 0001589150 RGBP:SeriesMMember 2022-03-31 0001589150 RGBP:SeriesMMember 2021-09-30 0001589150 RGBP:SeriesNCMember 2022-03-31 0001589150 RGBP:SeriesNCMember 2021-09-30 0001589150 2022-01-01 2022-03-31 0001589150 2021-01-01 2021-03-31 0001589150 2020-10-01 2021-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2020-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2020-09-30 0001589150 RGBP:SeriesNCPreferredStockMember 2020-09-30 0001589150 us-gaap:CommonStockMember 2020-09-30 0001589150 RGBP:SeriesMPreferredStockMember 2020-09-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001589150 us-gaap:RetainedEarningsMember 2020-09-30 0001589150 RGBP:ContributedCapitalMember 2020-09-30 0001589150 2020-09-30 0001589150 RGBP:PreferredStockSeriesAMember 2020-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2020-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2020-12-31 0001589150 us-gaap:CommonStockMember 2020-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2020-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001589150 us-gaap:RetainedEarningsMember 2020-12-31 0001589150 RGBP:ContributedCapitalMember 2020-12-31 0001589150 2020-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2021-09-30 0001589150 RGBP:SeriesNCPreferredStockMember 2021-09-30 0001589150 us-gaap:CommonStockMember 2021-09-30 0001589150 RGBP:SeriesMPreferredStockMember 2021-09-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001589150 us-gaap:RetainedEarningsMember 2021-09-30 0001589150 RGBP:ContributedCapitalMember 2021-09-30 0001589150 RGBP:PreferredStockSeriesAMember 2021-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-12-31 0001589150 us-gaap:CommonStockMember 2021-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001589150 us-gaap:RetainedEarningsMember 2021-12-31 0001589150 RGBP:ContributedCapitalMember 2021-12-31 0001589150 2021-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2020-10-01 2020-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2020-10-01 2020-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2020-10-01 2020-12-31 0001589150 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2020-10-01 2020-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001589150 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001589150 RGBP:ContributedCapitalMember 2020-10-01 2020-12-31 0001589150 2020-10-01 2020-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-01-01 2021-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-01-01 2021-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-01-01 2021-03-31 0001589150 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-01-01 2021-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001589150 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001589150 RGBP:ContributedCapitalMember 2021-01-01 2021-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-10-01 2021-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-10-01 2021-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-10-01 2021-12-31 0001589150 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-10-01 2021-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001589150 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001589150 RGBP:ContributedCapitalMember 2021-10-01 2021-12-31 0001589150 2021-10-01 2021-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2022-01-01 2022-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2022-01-01 2022-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2022-01-01 2022-03-31 0001589150 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2022-01-01 2022-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001589150 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001589150 RGBP:ContributedCapitalMember 2022-01-01 2022-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-03-31 0001589150 us-gaap:CommonStockMember 2021-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001589150 us-gaap:RetainedEarningsMember 2021-03-31 0001589150 RGBP:ContributedCapitalMember 2021-03-31 0001589150 2021-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2022-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2022-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2022-03-31 0001589150 us-gaap:CommonStockMember 2022-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2022-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001589150 us-gaap:RetainedEarningsMember 2022-03-31 0001589150 RGBP:ContributedCapitalMember 2022-03-31 0001589150 srt:MinimumMember 2021-10-01 2022-03-31 0001589150 srt:MaximumMember 2021-10-01 2022-03-31 0001589150 RGBP:ZanderTherapeuticsMember 2022-03-31 0001589150 2012-04-24 2022-03-31 0001589150 RGBP:DavidKoosMember 2022-03-31 0001589150 RGBP:DavidKoosMember 2022-03-31 0001589150 RGBP:DavidKoosMember 2021-10-01 2022-03-31 0001589150 RGBP:March82016Member 2022-03-31 0001589150 RGBP:April62016Member 2022-03-31 0001589150 RGBP:October312016Member 2022-03-31 0001589150 RGBP:October3120161Member 2022-03-31 0001589150 RGBP:October3120162Member 2022-03-31 0001589150 RGBP:March132017Member 2022-03-31 0001589150 RGBP:March132017Member 2021-10-01 2022-03-31 0001589150 RGBP:March312017Member 2022-03-31 0001589150 RGBP:March3120171Member 2022-03-31 0001589150 RGBP:March3120171Member 2021-10-01 2022-03-31 0001589150 RGBP:April192017Member 2022-03-31 0001589150 RGBP:May52017Member 2022-03-31 0001589150 RGBP:May52017Member 2021-10-01 2022-03-31 0001589150 RGBP:June262017Member 2022-03-31 0001589150 RGBP:June262017Member 2021-10-01 2022-03-31 0001589150 RGBP:Sept252017Member 2022-03-31 0001589150 RGBP:Sept252017Member 2021-10-01 2022-03-31 0001589150 RGBP:Oct0317Member 2022-03-31 0001589150 RGBP:Oct0317Member 2021-10-01 2022-03-31 0001589150 RGBP:Oct1617Member 2022-03-31 0001589150 RGBP:Oct1617Member 2021-10-01 2022-03-31 0001589150 RGBP:Nov0117Member 2022-03-31 0001589150 RGBP:Nov0117Member 2021-10-01 2022-03-31 0001589150 RGBP:Nov0120172Member 2022-03-31 0001589150 RGBP:Nov0120172Member 2021-10-01 2022-03-31 0001589150 RGBP:Dec2017Member 2022-03-31 0001589150 RGBP:Dec2017Member 2021-10-01 2022-03-31 0001589150 RGBP:Feb2818Member 2022-03-31 0001589150 RGBP:Feb2818Member 2021-10-01 2022-03-31 0001589150 RGBP:July112018Member 2022-03-31 0001589150 RGBP:July112018Member 2021-10-01 2022-03-31 0001589150 RGBP:September302018Member 2022-03-31 0001589150 RGBP:September302018Member 2021-10-01 2022-03-31 0001589150 RGBP:July192019Member 2022-03-31 0001589150 RGBP:September172021Member 2022-03-31 0001589150 RGBP:September172021Member 2021-10-01 2022-03-31 0001589150 RGBP:March172022Member 2022-03-31 0001589150 RGBP:ZanderTherapeuticsMember 2019-05-30 2019-06-11 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2019-11-01 2019-11-29 0001589150 RGBP:ZanderTherapeuticsMember 2021-10-01 2022-03-31 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2021-10-01 2022-03-31 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2022-03-31 0001589150 us-gaap:CommonStockMember RGBP:ZanderTherapeuticsMember 2022-03-31 0001589150 us-gaap:CommonStockMember RGBP:ZanderTherapeuticsMember 2021-10-01 2022-03-31 0001589150 RGBP:UnrelatedPartyMember 2021-04-01 2021-06-30 0001589150 RGBP:UnrelatedPartyMember 2021-07-01 2021-09-30 0001589150 us-gaap:CommonStockMember 2022-03-31 0001589150 us-gaap:CommonStockMember RGBP:OncologyPharmaMember 2022-03-31 0001589150 us-gaap:CommonStockMember RGBP:OncologyPharmaMember 2021-10-01 2022-03-31 0001589150 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-03-01 2022-03-28 0001589150 us-gaap:SubsequentEventMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-04-01 2022-04-04 0001589150 us-gaap:SubsequentEventMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-04-01 2022-04-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 For the quarterly period ended March 31, 2022

 

  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 For the transition period from

 

 Commission File No. 333-191725

 

 REGEN BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

 

Nevada 45-5192997
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

 

4700 Spring StreetSt 304La MesaCalifornia 91942

(Address of Principal Executive Offices)

 

619 722-5505

(Issuer’s telephone number)

 

None

(Former name, address and fiscal year, if changed since last report)

 

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒   No  

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☐  No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

☐  Large accelerated filer ☐  Accelerated filer
☐  Non-accelerated filer   Smaller reporting company
   Emerging Growth Company 

APPLICABLE ONLY TO CORPORATE ISSUERS:

As of April 7, 2022 Regen Biopharma, Inc. had 4,736,002,832  common shares outstanding.

As of April 7,2022 Regen Biopharma, Inc. had 439,293,406 shares of Series A Preferred Stock outstanding.

As of April 7, 2022 Regen Biopharma, Inc. had 50,000 shares of Series AA Preferred Stock outstanding.

As of April 7, 2022 Regen Biopharma, Inc. had 44,000,000 shares of Series M Preferred Stock outstanding.

As of April 7, 2022 Regen Biopharma, Inc. had 10,000 shares of Series NC Preferred Stock outstanding

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

Yes ☐ No ☒

 1 

 

 

PART I - FINANCIAL INFORMATION

Item 1. - Financial Statements

           
REGEN BIOPHARMA , INC.      
CONDENSED CONSOLIDATED BALANCE SHEETS      
       
       
   As of March 31, 2022  As of September 30, 2021
   (Unaudited)   
ASSETS      
CURRENT ASSETS          
Cash  $234,674   $727,162 
Accounts Receivable, Related Party   268,042    213,192 
Note Receivable, Related Party   5,396    5,396 
Accrued Interest Receivable   496    230 
Prepaid Expenses   34,582    48,144 
     Total Current Assets   543,190    994,124 
OTHER ASSETS          
Investment Securities   67,710    198,006 
Investment Securities, Related Party   19,969    19,969 
Total Other Assets   87,679    217,975 
TOTAL ASSETS  $630,869   $1,212,099 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current Liabilities:          
Accounts payable   41,629    91,498 
Notes Payable   227    1,429,179 
Accrued payroll taxes   4,241    4,241 
Accrued Interest   664,787    954,861 
Accrued Rent        0 
Accrued Payroll   1,266,679    1,266,679 
Other Accrued Expenses   41,423    41,423 
Bank Overdraft   1,000    1,000 
Due to Investor   20,000    20,000 
Unearned Income   1,781,222    1,843,806 
Derivative Liability   70,561,820    6,892,477 
Convertible Notes Payable Less  unamortized discount   2,987,270    2,131,311 
Convertible Notes Payable, Related Parties Less  unamortized discount   10,000    21,500 
Total Current Liabilities   77,380,299    14,697,976 
Long Term Liabilities:          
Convertible Notes Payable, Related Parties Less  unamortized discount        0 
Total Long Term Liabilities          
Total Liabilities   77,380,299    14,697,976 
           
STOCKHOLDERS' EQUITY (DEFICIT)          
Common Stock ($.0001 par value) 500,000,000 shares authorized; 5,800,000,000 authorized and 4,580,002,832 issued and outstanding as of March 31,2022 and 4,800,000,000 authorized and 4,350,554,514 shares issued and outstanding as of September 30 ,2021.   457,999    435,054 
Preferred Stock, 0.0001 par value, 800,000,000 authorized as of          
March  31,2022  and September 30,2021 respectively          
Series A Preferred 300,000,000 authorized as of September 30,2021 and 540,000,000 authorized as of March 31, 2022; 439,293,406 and 431,998,817 outstanding as of  March 31,2022 and September 30, 2021 respectively   43,929    43,200 
Series AA Preferred $0.0001 par value 600,000 authorized and 50,000 and 50,000   outstanding as of March 31, 2022 and September 30,2021 respectively   5    5 
Series M Preferred $0.0001 par value 300,000,000 authorized and  44,000,000 outstanding as of September 30,2021 and 60,000,000 authorized and 44,000,000 outstanding as of March 31, 2022   4,400    4,400 
Series NC Preferred $0.0001 par value 20,000  authorized and 10,000  outstanding as of September 30, 2021 and March 31,2022 respectively   1    1 
Additional Paid in capital   9,793,419    8,644,037 
Contributed Capital   736,326    736,326 
Retained Earnings (Deficit)   (87,785,509)   (23,348,900)
Total Stockholders' Equity (Deficit)   (76,749,430)   (13,485,877)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)  $630,869   $1,212,099 
           
The Accompanying Notes are an Integral Part of These Financial Statements

 2 

 

                     
REGEN BIOPHARMA , INC.            
CONDENSED CONSOLIDATED  STATEMENTS OF OPERATIONS      
( Unaudited)            
             
    Quarter Ended March 31, 2022    Quarter Ended March 31, 2021    Six Months Ended March 31, 2022    Six Months Ended March 31, 2021 
REVENUES                    
Revenues  $30,945   $     $62,584   $   
Revenues, Related Party   27,425    27,425    54,849    54,849 
TOTAL REVENUES   58,369    27,425    117,434    54,849 
COST AND EXPENSES                    
Research and Development   27,390    512    62,809    1,639 
Research and Development, Related Party   36,975    0    117,250    0 
General and Administrative   5,355    39,886    12,013    84,664 
Consulting and Professional Fees   50,143    0    88,279    0 
Rent   15,000    0    20,000    0 
Total Costs and Expenses   134,863    40,398    300,351    86,303 
OPERATING INCOME (LOSS)  $(76,494)  $(12,973)  $(182,917)  $(31,453)
                     
OTHER INCOME & (EXPENSES)                    
Interest Income   131    0    266    0 
Interest Expense   (42,561)   (65,247)   (77,571)   (138,459)
Interest Expense attributable to Amortization of Discount   (21,977)   (9,932)   (44,428)   (46,649)
Penalties   (300,000)   0    (300,000)   0 
Unrealized Gain ( Loss) on sale of Investment Securities   (6,405)   0    (130,296)   0 
Gain (Loss) on derecognition of Accounts Payable   0    0    62,700    0 
Derivative Income (Expense)   (66,634,282)   530,335    (63,669,343)   2,325,111 
Gain (Loss) on  Extinguishment Convertible Debt   0         (95,019)   0 
TOTAL OTHER INCOME (EXPENSE)   (67,005,095)   455,156    (64,253,692)   2,140,002 
                     
NET INCOME (LOSS)  $(67,081,589)  $442,183   $(64,436,609)  $2,108,549 
NET INCOME (LOSS) attributable to common shareholders  $(67,081,589)  $382,046   $(64,436,609)  $1,821,787 
                     
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE  $(0.015)  $0.0002   $(0.014)  $0.00086 
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING   4,564,542,158    2,457,641,499    4,535,585,981    2,125,778,002 
                     
The Accompanying Notes are an Integral Part of These Financial Statements

 3 

 

 

                                                                            
REGEN BIOPHARMA , INC.
Condensed Consolidated Statement of Shareholder's Deficit
(Unaudited)
                                              
                                              
   Series A  Preferred  Series AA Preferred  Series NC Preferred  Common  Series M Peferred               
   Shares  Amount  Shares  Amount  Shares  Amount  Shares  Amount  Shares  Amount  Additional Paid-in Capital  Retained Earnings  Contributed Capital  Total   
Balance September 30, 2020   381,768,689   $38,177    50,000    5              1,605,000,246   $160,498    44,000,000   $4,400   $8,313,876   $(16,583,666)  $731,711   $(7,334,998)     
Shares issued for Debt                                 57,726,183    5,773              (2,021)             3,752      
Shares Issued For Interest                                 22,339,663    2,234              (782)             1,452      
Shares issued for Debt                                 60,007,919    6,001              (2,101)             3,900      
Shares Issued For Interest                                 23,926,234    2,393              (838)             1,555      
Shares issued for Debt                                 60,834,498    6,083              1,217              7,300      
Shares Issued For Interest                                 26,185,501    2,619              523              3,142      
Shares issued for Debt                                 3,300,000    330              99              429      
Shares Issued For Interest                                 1,819,077    182              54              236      
Shares issued for Fees                                 1,228,077    123              36              159      
Shares issued for Debt                                 62,003,571    6,200              (2,170)             4,030      
Shares Issued For Interest                                 26,155,352    2,616              (916)             1,700      
Shares issued for Debt                                 68,333,539    6,833              1,367              8,200      
Shares Issued For Interest                                 14,883,378    1,488              212              1,700      
Shares issued for Debt   20,000,437    2,000                                            11,000              13,000      
Shares Issued For Interest   12,378,732    1,238                                            6,808              8,046      
Shares Issued for Debt                                 88,888,889    8,889              7,111              16,000      
Shares Issued For Interest                                 19,555,555    1,956              1,294              3,250      
Shares issued for Debt                                 82,004,603    8,200              (2,870)             5,330      
Shares Issued For Interest                                 35,832,781    3,583              (1,254)             2,329      
Additions to Contributed Capital                                                               1,865    1,865      
Net Loss                                                         1,666,367         1,666,367      
Balance December 31, 2020   414,147,858   $41,415    50,000    5              2,260,025,066   $226,001    44,000,000   $4,400   $8,330,646   $(14,917,299)  $733,576   $(5,581,256)     
shares issued for debt                                 85,900,000    8,590              (3,436)             5,154      
shares issued for interest                                 88,000,000    8,800              (4,400)             4,400      
shares issued for debt                                 71,430,421    7,143              22,857              30,000      
shares issued for interest                                 11,328,865    1,133              3,625              4,758      
shares issued for debt                                 80,928,505    8,093              (2,833)             5,260      
shares issued for interest                                 38,341,033    3,834              (1,342)             2,492      
shares issued for debt                                 67,175,355    6,718              (3,361)             3,357      
shares issued for interest                                 8,824,645    882              (441)             441      
shares issued for debt                                 16,666,667    1,667              (667)             1,000      
shares issued for interest                                 95,833,333    9,583              (3,833)             5,750      
shares issued for debt                                 68,319,520    6,832              (3,417)             3,415      
shares issued for interest                                 1,680,480    168              (84)             84      
shares issued for debt                                 38,519,260    3,852              (1,927)             1,925      
shares issued for interest                                 1,480,740    148              (74)             74      
Additions to Contributed Capital                                                               250    250      
Net Income                                                          442,183         4,421,825,363      
Balance March 31, 2021   414,147,858   $41,415    50,000    5    0    0    2,934,453,890   $293,444    44,000,000   $4,400   $8,331,313   $(14,475,117)  $733,826   $(5,070,713)     
Balance September 30, 2021   431,998,817   $43,200    50,000   $5    10,000   $1    4,350,554,514   $435,054    44,000,000   $4,400   $8,644,037   $(23,348,900)  $736,326   $(13,485,877)     
Shares issued for Debt                                 10,000,000    1,000              99,000              100,000      
Shares issued for Interest                                 2,666,200    267              26,395              26,662      
Shares issued for Debt                                 10,000,000    1,000              99,000              100,000      
Shares issued for Interest                                 3,883,700    388              38,449              38,837      
Shares issued for Debt                                 6,022,971    602              49,398              50,000      
Shares issued for Interest                                 2,361,366    236              19,367              19,603      
Shares issued for Debt                                 15,503,953    1,550              48,450              50,000      
Shares issued for Interest                                 5,759,719    576              17,999              18,575      
Shares issued for Interest                                 23,255,888    2,326              72,674              75,000      
Shares issued for Debt                                 9,945,768    995              31,080              32,075      
Shares issued for Interest                                 7,751,973    775              24,225              25,000      
Shares issued for Interest                                 3,211,178    321              10,035              10,356      
Shares issued for Debt                                 1,000,016    100              24,900              25,000      
Shares issued for Interest                                 355,326    36              8,847              8,883      
Shares issued for Debt   4,000,047    400                                            49,600              50,000      
Shares issued for Interest   1,869,542    187                                            23,182              23,369      
Shares issued for Debt                                 10,256,427    1,026